Werewolf Therapeutics/$HOWL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Werewolf Therapeutics
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Ticker
$HOWL
Sector
Primary listing
Employees
46
Headquarters
Website
HOWL Metrics
BasicAdvanced
$60M
-
-$1.64
-
-
Price and volume
Market cap
$60M
52-week high
$3.26
52-week low
$0.60
Average daily volume
282K
Financial strength
Current ratio
5.302
Quick ratio
5.115
Long term debt to equity
80.291
Total debt to equity
89.586
Interest coverage (TTM)
-14.39%
Profitability
EBITDA (TTM)
-71.277
Management effectiveness
Return on assets (TTM)
-37.06%
Return on equity (TTM)
-100.55%
Valuation
Price to book
1.45
Price to tangible book (TTM)
1.45
Price to free cash flow (TTM)
-0.971
Free cash flow yield (TTM)
-102.98%
Free cash flow per share (TTM)
-1.37
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
17.30%
3-year earnings per share growth (CAGR)
-9.88%
What the Analysts think about HOWL
Analyst ratings (Buy, Hold, Sell) for Werewolf Therapeutics stock.
HOWL Financial Performance
Revenues and expenses
HOWL Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Werewolf Therapeutics stock?
Werewolf Therapeutics (HOWL) has a market cap of $60M as of August 18, 2025.
What is the P/E ratio for Werewolf Therapeutics stock?
The price to earnings (P/E) ratio for Werewolf Therapeutics (HOWL) stock is 0 as of August 18, 2025.
Does Werewolf Therapeutics stock pay dividends?
No, Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders as of August 18, 2025.
When is the next Werewolf Therapeutics dividend payment date?
Werewolf Therapeutics (HOWL) stock does not pay dividends to its shareholders.
What is the beta indicator for Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) does not currently have a Beta indicator.